LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

BACKGROUND: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Schimanski, Carl Christoph, Möhler, Markus, Schön, Michael, van Cutsem, Eric, Greil, Richard, Bechstein, Wolf Otto, Hegewisch-Becker, Susanna, von Wichert, Götz, Vöhringer, Matthias, Heike, Michael, Heinemann, Volker, Peeters, Marc, Kanzler, Stephan, Kasper, Stefan, Overkamp, Friedrich, Schröder, Jan, Seehofer, Daniel, Kullmann, Frank, Linz, Bernhard, Schmidtmann, Irene, Smith-Machnow, Victoria, Gockel, Ines, Lang, Hauke, Galle, Peter R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342924/
https://www.ncbi.nlm.nih.gov/pubmed/22494623
http://dx.doi.org/10.1186/1471-2407-12-144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342924/
https://www.ncbi.nlm.nih.gov/pubmed/22494623
http://dx.doi.org/10.1186/1471-2407-12-144

Ejemplares similares